<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615805</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #9810</org_study_id>
    <nct_id>NCT05615805</nct_id>
  </id_info>
  <brief_title>The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections</brief_title>
  <official_title>The Effect of Ocular Rinse Volume on Surface Irritation After Povidone-iodine Preparation for Intravitreal Injections: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first randomized controlled trial looking into post-injection rinse volume of&#xD;
      standard ophthalmic eyewash and its affect on patient comfort up to 72 hours after&#xD;
      injections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose To evaluate whether the volume of wash out rinse after povidone iodine (PI)&#xD;
      application for intravitreal injections (IVI) affects patients' ocular surface irritation.&#xD;
&#xD;
      Methods This was a prospective, single-masked, randomized-controlled trial consisting of 142&#xD;
      subjects . A total of 51, 45, and 46 patients received 3-mL, 10-mL, and 15-mL of ocular rinse&#xD;
      respectively. Reductions in the Ocular Surface Disease Index (OSDI) and the Standardized&#xD;
      Patient Evaluation of Eye Dryness II (SPEED II) surveys, conducted before and at 24-72 hours&#xD;
      post-injection, were analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Index</measure>
    <time_frame>24-72 hours after injection</time_frame>
    <description>Patient symptoms questionnaire, range 0-28, higher score is associated with worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standardized Patient Evaluation of Eye Dryness II</measure>
    <time_frame>24-72 hours after injection</time_frame>
    <description>Patient symptoms questionnaire, range 0-48, higher score is associated with worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Intravitreal Injection</condition>
  <condition>Ocular Rinse</condition>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Cystoid Macular Edema</condition>
  <arm_group>
    <arm_group_label>3-mL washout with saline based ocular rinse post injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10-mL washout with saline based ocular rinse post injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>15-mL washout with saline based ocular rinse post injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OSDI questionnaire</intervention_name>
    <description>Ocular Surface Disease Index</description>
    <arm_group_label>10-mL washout with saline based ocular rinse post injection</arm_group_label>
    <arm_group_label>15-mL washout with saline based ocular rinse post injection</arm_group_label>
    <arm_group_label>3-mL washout with saline based ocular rinse post injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SPEEDII questionnaire</intervention_name>
    <description>Standardized Patient Evaluation of Eye Dryness II questionnaire</description>
    <arm_group_label>10-mL washout with saline based ocular rinse post injection</arm_group_label>
    <arm_group_label>15-mL washout with saline based ocular rinse post injection</arm_group_label>
    <arm_group_label>3-mL washout with saline based ocular rinse post injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        choroidal neovascular membrane or cystoid macular edema requiring intravitreal injections&#xD;
        for treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        active ocular infection, eyelid trauma, graft versus host disease, thyroid eye disease,&#xD;
        pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dean McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>October 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>April 21, 2023</last_update_submitted>
  <last_update_submitted_qc>April 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Depending on their required use of the data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

